CVE-2018-10392

Public Exploit

Description

mapping0_forward in mapping0.c in Xiph.Org libvorbis 1.3.6 does not validate the number of channels, which allows remote attackers to cause a denial of service (heap-based buffer overflow or over-read) or possibly have unspecified other impact via a crafted file.

Category

8.8
CVSS
Severity: High
CVSS 3.1 •
CVSS 2.0 •
EPSS 1.36% Top 25%
Vendor Advisory redhat.com Vendor Advisory gentoo.org Vendor Advisory xiph.org
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://gitlab.xiph.org/xiph/vorbis/issues/2335 vendor advisory issue tracking exploit
https://access.redhat.com/errata/RHSA-2019:3703 third party advisory vendor advisory
https://lists.debian.org/debian-lts-announce/2019/11/msg00031.html third party advisory mailing list
https://security.gentoo.org/glsa/202003-36 third party advisory vendor advisory
https://lists.debian.org/debian-lts-announce/2021/11/msg00023.html third party advisory mailing list

Frequently Asked Questions

What is the severity of CVE-2018-10392?
CVE-2018-10392 has been scored as a high severity vulnerability.
How to fix CVE-2018-10392?
To fix CVE-2018-10392, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2018-10392 being actively exploited in the wild?
It is possible that CVE-2018-10392 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.